Decoy Therapeutics filed for an offering of up to 808,000 common shares by selling stockholders on June 15, 2026. This follows a June 12 S-1 filing registering the shares for resale under a committed equity financing facility. The pre-clinical biotech firm develops peptide conjugate therapeutics.
Management and auditors expressed substantial doubt regarding the company's ability to continue as a going concern. Current cash reserves are expected to fund operations only into late 2026.
The offering represents a potential 60% dilution of post-issuance shares outstanding.